Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants br
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY(2022)
Abstract
The rapid emergence and spread of escaping mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly challenged our efforts infighting against the COVID-19 pandemic. A broadly neutralizing reagent againstthese concerning variants is thus highly desirable for the prophylactic and therapeutic treatments of SARS-CoV-2 infection. Weherein report a covalent engineering strategy on protein minibinders for potent neutralization of the escaping variants such asB.1.617.2 (Delta), B.1.617.1 (Kappa), and B.1.1.529 (Omicron) through in situ cross-linking with the spike receptor binding domain(RBD). The resulting covalent minibinder (GlueBinder) exhibited enhanced blockage of RBD-human angiotensin-convertingenzyme 2 (huACE2) interaction and more potent neutralization effect against the Delta variant than its noncovalent counterpart asdemonstrated on authentic virus. By leveraging the covalent chemistry against escaping mutations, our strategy may be generally applicable for restoring and enhancing the potency of neutralizing antibodies to SARS-CoV-2 and other rapidly evolving viral targets.
MoreTranslated text
Key words
protein minibinders,sars-cov
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined